Skip to main content

Sodium Oxybate Beneficial for Alcohol-Responsive Laryngeal Dystonia

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on Nov 27, 2024.

via HealthDay

WEDNESDAY, Nov. 27, 2024 -- Sodium oxybate improves symptoms of alcohol-responsive (EtOH-positive) isolated laryngeal dystonia (LD), according to a study published online Nov. 20 in the Annals of Neurology.

Kristina Simonyan, M.D., Ph.D., from Massachusetts Eye and Ear and Harvard Medical School in Boston, and colleagues examined the efficacy and safety of sodium oxybate versus placebo in a phase 2b randomized, crossover clinical trial involving patients with isolated LD. The study was conducted in 106 patients with EtOH-positive and alcohol-non-responsive (EtOH-negative) LD who were randomly assigned to receive 1.5 g sodium oxybate first or matching placebo first (53 each). The change from baseline in LD symptom severity 40 minutes after drug intake was assessed as the primary outcome.

The researchers found that EtOH-positive but not EtOH-negative patients had a significant improvement in LD symptoms following sodium oxybate versus placebo compared with baseline. In EtOH-positive patients, statistically significant minimum drug efficacy was found at ≥16 percent symptom improvement (odds ratio, 2.09), with an average benefit of 40.81 percent. By 300 minutes after intake, drug efficacy waned, without a rebound. There were no changes in cognitive function, suicide, or vital signs. Mild dizziness, nausea, and daytime sleepiness were common adverse events.

"Our findings suggest that sodium oxybate can be taken on an as-needed basis, such as before work or a social event, so patients can tailor treatment to their own daily needs and get in control of their symptoms," Simonyan said in a statement.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Canagliflozin Tied to Reduction in HbA1c in Children, Teens With T2DM

WEDNESDAY, Aug. 6, 2025 -- Canagliflozin is associated with a clinically meaningful reduction in hemoglobin A1c (HbA1c) for children and adolescents with type 2 diabetes mellitus...

About One in Six Men With Grade Group 1 Prostate Cancer Has Intermediate-, High-Risk Disease

WEDNESDAY, Aug. 6, 2025 -- A proportion of men with grade group 1 (GG1) prostate cancer have a higher-risk disease than suggested by biopsy, according to a study published online...

Follow-Up on Blood-Based Colorectal Cancer Screening Results Is Low

TUESDAY, Aug. 5, 2025 -- Just under half of patients receiving an abnormal blood-based colorectal cancer screening test result receive a follow-up colonoscopy (FU-CY) within...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.